Japan-based pharmaceutical manufacturer Delta-Fly Pharma Inc (TOKYO: 4598) announced on Wednesday that it has commenced patient enrollment for its Phase III clinical trial of DFP-14323 in combination with Afatinib (20 mg/day) versus Afatinib (40 mg/day) alone in stage III/IV non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations.
Approved by the Pharmaceuticals and Medical Devices Agency (PMDA) in February 2024, this trial will be conducted at 30 sites in Japan.
The primary endpoint is to confirm the superiority of DFP-14323 in progression-free survival (PFS). DFP-14323 targets aminopeptidase N, which is highly expressed in lung cancer and inflammatory cells, potentially offering effective treatment for refractory cancer patients regardless of EGFR mutation types.
Plans are underway to expand the trial to other Asian countries with high numbers of EGFR mutation-positive NSCLC patients. Delta-Fly Pharma will also seek out-licensing opportunities with Asian pharmaceutical companies.
Ananda's cannabinoid medicines to feature in NHS epilepsy trials
AstraZeneca's Wainzua recommended for EU approval
Avacta Group partners with Tempus to enhance AI-driven oncology drug development
PharmaLogic opens new radiopharmaceutical facility in Salt Lake City
Astellas Pharma's VYLOY receives US FDA approval
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
SHINE Technologies collaboration could result in new kidney and prostate cancer treatments
Elysium Health launches VISION for visual performance and eye health
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial
Innovent Biologic meets primary endpoint in picankibart phase 2 study